U.S. Markets closed

Veru Inc. (VERU)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.77+0.21 (+2.78%)
At close: 4:00PM EDT

7.77 0.00 (0.00%)
After hours: 7:28PM EDT

Veru Inc.

48 NW 25th Street
Suite 102
Miami, FL 33127
United States

Full Time Employees339

Key Executives

NameTitlePayExercisedYear Born
Dr. Mitchell S. Steiner F.A.C.S., M.D., F.A.C.SChairman, Pres & CEO874.6kN/A1961
Dr. Harry FischVice Chairman & Chief Corp. Officer465.02kN/A1959
Ms. Michele GrecoCFO & Chief Admin. Officer443.72kN/A1959
Dr. K. Gary Barnette Ph.D.Chief Scientific Officer507.01kN/A1968
Mr. Samuel FischDirector of Investor RelationsN/AN/AN/A
Mr. Michael J. PurvisVP, Gen. Counsel & Corp. StrategyN/AN/AN/A
Mr. Kevin J. Gilbert CPA, J.D.Exec. VP of Corp. Devel.N/AN/AN/A
Dr. Robert H. GetzenbergExec. VP for Medical AffairsN/AN/AN/A
Mr. Phillip KuhnExec. VP of Strategy & CommercialN/AN/AN/A
Dr. Domingo RodriguezExec. VP of Clinical OperationsN/AN/A1962
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include VERU-111, an oral chemical entity that is being evaluated in open label Phase 1b and Phase 2 clinical trials in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer, as well as being evaluated in a Phase 2 clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome; and for the treatment of taxane resistant metastatic triple negative breast cancer. Its drug candidates also comprise VERU-100, a gonadotropin-releasing hormone antagonist peptide formulation to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. In addition, the company's drug candidates include Enobosarm, an oral selective androgen receptor agonist that targets the androgen receptor positive, estrogen receptor positive, and human epidermal growth factor receptor 2 metastatic breast cancer without the unwanted virilizing side effects. Further, it is advancing a new drug formulation in its specialty pharmaceutical pipeline addressing unmet medical needs in urology, such as Tadalafil and Finasteride Combination. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. is headquartered in Miami, Florida.

Corporate Governance

Veru Inc.’s ISS Governance QualityScore as of April 30, 2021 is 5. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 4; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.